Vir Biotechnology (VIR) Accumulated Depreciation (2018 - 2023)

Vir Biotechnology has disclosed Accumulated Depreciation across 6 years of filings, most recently posting $26.2 million for Q1 2023.

• Accumulated Depreciation for Q1 2023 came in at $26.2 million, up 65.06% year-over-year; the trailing twelve-month figure through Mar 2023 was $26.2 million (up 65.06% YoY), and the FY2022 annual result was $20.7 million, up 43.13% from the prior year.
• Accumulated Depreciation came in at $26.2 million for Q1 2023 at Vir Biotechnology, up from $20.7 million in the prior quarter.
• In the past five years, Accumulated Depreciation ranged from a high of $26.2 million in Q1 2023 to a low of $4.2 million in Q3 2019.
• The 5-year median for Accumulated Depreciation is $11.8 million (2021), against an average of $12.5 million.
• Across the five-year window, Accumulated Depreciation jumped 181.59% in 2019 and jumped 43.13% in 2022, its largest moves.
• Vir Biotechnology's Accumulated Depreciation stood at $4.8 million in 2019, then soared by 91.06% to $9.2 million in 2020, then surged by 56.98% to $14.5 million in 2021, then soared by 43.13% to $20.7 million in 2022, then grew by 26.54% to $26.2 million in 2023.
• The last three Accumulated Depreciation figures came in at $26.2 million (Q1 2023), $20.7 million (Q4 2022), and $18.9 million (Q3 2022), per Business Quant data.